P. Schofield

发表

Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesity.

S. Boyer, C. Donald, A. Turnbull, 2002, Journal of medicinal chemistry.

Novel thienopyrrole glycogen phosphorylase inhibitors: synthesis, in vitro SAR and crystallographic studies.

Paul M. Murray, L. Otterbein, N. Oikonomakos, 2006, Bioorganic & medicinal chemistry letters.

Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists.

Hayley S. Brown, D. Laber, James S. Scott, 2014, Journal of medicinal chemistry.

Organotin-substituted organosiloxanes: Synthesis and characterisation, including the crystal structure of 1,3-bis(triphenylstannoxy)-1,1,3,3-tetraphenyl-1,3-disiloxane

K. Molloy,, M. Mahon, P. Schofield, 1994 .

Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human.

Hayley S. Brown, D. Laber, James S. Scott, 2013, Bioorganic & medicinal chemistry letters.

Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 1.

C. Charrier, M. Craighead, J. Maclean, 2020, RSC medicinal chemistry.

Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes.

Andrew G. Leach, A. Plowright, Robert D. M. Davies, 2012, Bioorganic & medicinal chemistry letters.

Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation.

Andrew G. Leach, Hayley S. Brown, D. Laber, 2012, Journal of medicinal chemistry.

Discovery, optimisation and in vivo evaluation of novel GPR119 agonists.

Andrew G. Leach, Hayley S. Brown, James S. Scott, 2011, Bioorganic & medicinal chemistry letters.

Synthesis and structural characterization of cycloborasiloxanes: The X-ray crystal structures of cyclo-1,3,3,5,5-pentaphenyl-1-bora-3,5-disiloxane and cyclo-1,3,3,5,7,7-hexaphenyl-1,5-dibora-3,7-disiloxane

M. Mahon, P. Schofield, B. J. Brisdon, 1992 .

Development of potent, orally active 1-substituted-3,4-dihydro-2-quinolone glycogen phosphorylase inhibitors.

L. Otterbein, N. Oikonomakos, P. Kenny, 2007, Bioorganic & medicinal chemistry letters.

Making medicinal chemistry more effective--application of Lean Sigma to improve processes, speed and quality.

Nidhal Selmi, Jan Kihlberg, Magnus J. Johansson, 2009, Drug discovery today.

Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017).

Martin J Packer, Nidhal Selmi, David Hargreaves, 2012, Journal of medicinal chemistry.

Reduction of acyl glucuronidation in a series of acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors: the discovery of AZD6925

James S. Scott, N. Selmi, M. Packer, 2012 .

Optimisation of aqueous solubility in a series of G protein coupled receptor 119 (GPR119) agonists

Andrew G. Leach, Hayley S. Brown, James S. Scott, 2013 .

Optimisation of pharmacokinetic properties in a neutral series of 11β-HSD1 inhibitors.

A. Gill, James S. Scott, J. Swales, 2012, Bioorganic & medicinal chemistry letters.

Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists.

Andrew G. Leach, Hayley S. Brown, D. Laber, 2014, Journal of medicinal chemistry.